Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON24855
NL-OMON24855
Not yet recruiting
Not Applicable

An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes

niversity Medical Center Groningen (UMCG)0 sites17 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDiabetes Mellitus Type 2 (DM type II), Albuminuria

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus Type 2 (DM type II), Albuminuria
Sponsor
niversity Medical Center Groningen (UMCG)
Enrollment
17
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
niversity Medical Center Groningen (UMCG)

Eligibility Criteria

Inclusion Criteria

  • •Type 2 diabetes
  • •HbA1c ≥ 7\.5% (58 mmol/mol) and \<10% (86 mmol/mol)

Exclusion Criteria

  • •Pregnant women and women of child\-bearing potential who are not using
  • •reliable contraception

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetesdiabetesDiabetes Mellitus10012653
NL-OMON46820Martini Ziekenhuis20
Active, not recruiting
Phase 1
Study to evaluate the effect of dapagliflozin, exenatide and their combination on the loss of protein in urine in patients with type 2 diabetes
EUCTR2017-004709-42-NLMartini Hospital17
Completed
Not Applicable
An open-label, randomized crossover study to evaluate the pharmacokinetics, bioavailability, bioequivalence, and food effect following administration of Oxybate Formulations in healthy subjects.
NL-OMON41817Jazz Pharmaceuticals60
Completed
Not Applicable
An open-label, randomized crossover study to evaluate the effect of ASP1941 on the pharmacokinetics, pharmacodynamics, safety and tolerability of glimepiride in healthy subjects and vice versa.
NL-OMON34715Astellas Pharma26
Completed
Not Applicable
A randomized, open-label, crossover study to evaluate ICS/LABA treatment versus LAMA/LABA treatment in COPD with eosinophilic inflammatioCOPD
JPRN-UMIN000024905Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital25